Fine Foods & Pharmaceuticals N.t.m. Spa MIL:FF

Fine Foods & Pharmaceuticals N T M S p A : Interim Financial Report as of 31 March 2026

Published May 12, 2026 at 12:52 p.m. UTC

Source: MarketScreener

FINE FOODS & PHARMACEUTICALS N.T.M. S.p.A.

Registered office: VIA BERLINO 39 VERDELLINO (BG) Registered in the BERGAMO Companies Register

Tax code and Company reference number: 09320600969 Registered in the BERGAMO REA no. 454184 Subscribed share capital € 22,770,445.02 Fully paid up VAT number: 09320600969

Interim Financial Report as of 31 March 2026

07 May 2026 Board of Directors

Table of contents

Corporate positions	page	3
Consolidated Income Statement	"	5
Consolidated Financial Position Statement	"	6
Consolidated Cash Flow Statement	"	7
Consolidated Shareholders' Equity Changes Statement	"	8
Explanatory Notes	"	9
Declaration of the Manager in charge under Article 154-bis of Legislative Decree no. 58/98	"	15

CORPORATE POSITIONS

Board of Directors Chairman and CEO

Marco Francesco Eigenmann

Managing Director

Pietro Oriani

Directors

Ada Imperadore Adriano Pala Ciurlo Deborah Maria Venturini Elena Sacco

Giovanni Eigenmann Marco Costaguta Paolo Ferrario Susanna Pedretti

Board of Statutory Auditors Chairman

Guido Croci

Statutory Auditors Ottavia Alfano Massimo Pretelli Auditing Company

EY S.p.A.

Manager responsible for preparing the Company's Financial Reports

Pietro Bassani

Appointed by the Board of Directors on 21 April 2021 under Article 27-bis of the Articles of Association.

Committees Control and Risk Committee

Ada Imperadore Elena Sacco Susanna Pedretti

Supervisory Body Cristiana Renna Paolo Villa Susanna Pedretti Remuneration Committee

Ada Imperadore Elena Sacco Susanna Pedretti

Related Party Committee

Ada Imperadore Elena Sacco Susanna Pedretti

Environmental, Social and Governance (ESG) Committee

Ada Imperadore Deborah Maria Venturini Pietro Oriani

Consolidated Income Statement

(amounts in € units)	3 months 31 March 2026	3 months 31 March 2025
Revenue and income
Revenue from contracts with customers	58,448,942	62,996,851
Other revenue and income	276,509	301,280
Total revenue	58,725,451	63,298,131
Operating costs
Costs for consumption of raw materials, change in inventories of finished goods and work in progress.	30,505,221	33,714,597
Personnel costs	14,177,645	13,295,829
Costs for services	6,712,362	5,909,711
Other operating costs	372,613	487,586
Amortisation, depreciation, and impairment losses	4,789,093	3,815,421
Total operating costs	56,556,934	57,223,143
Operating result	2,168,517	6,074,989
Financial income	13,198	22,716
Financial charges	(711,919)	(701,358)
Income before taxes	1,469,796	5,396,347
Income taxes	639,384	1,359,389
Profit/(loss) for the financial year	830,412	4,036,957

Consolidated Comprehensive Income Statement

(amounts in € units)	3 months 31 March 2026	3 months 31 March 2025
Profit /(loss) for the financial year (A)	830,412	4,036,957
Components that will not be subsequently reclassified to profit/(loss) for the financial year
Revaluation of net employee benefit liabilities/assets	-	-
Tax effect	-	-
Other comprehensive income (B) components	-	-

Comprehensive profit/(loss) (A+B)	830,412	4,036,957

Consolidated Financial Position Statement

	As of 31 March	As of 31 December
(amounts in € units)	2026	2025
Assets
Non-current assets
Property, plant and machinery	146,450,186	144,157,789
Goodwill	11,507,954	11,507,954
Other intangible fixed assets	1,918,254	1,924,298
Rights of use	2,950,294	2,894,651
Other non-current assets	131,018	324,052
Deferred tax assets	1,844,185	1,864,403
Total non-current assets	164,801,891	162,673,147
Current assets
Inventories	37,531,333	34,954,626
Trade receivables	39,635,988	36,606,666
Tax receivables	16,622	47,368
Other current assets	8,679,318	6,859,387
Cash and other liquid assets	24,939,514	38,882,901
Total current assets	110,802,776	117,350,948

Total assets	275,604,667	280,024,095
Shareholders' equity
Share Capital	22,770,445	22,770,445
Other reserves	100,212,554	106,946,489
Employee benefit reserve	251,002	251,002
FTA reserve	(6,669,789)	(6,669,789)
Profits carried forward	10,907,576	810,290
Profit/(loss) for the financial year	830,412	10,097,286
Total Shareholders' Equity	128,302,200	134,205,722
Non-current liabilities
Non-current bank borrowings	70,237,834	72,736,116
Employee benefits	1,935,536	1,922,357
Provision for risks and charges	2,884,980	2,710,805
Provision for deferred taxes	303,172	303,792
Non-current lease payables	946,670	899,666
Total non-current liabilities	76,308,192	78,572,737
Current liabilities
Current bank borrowings	14,331,723	12,752,615
Trade payables	36,434,448	36,351,971
Taxes payable	1,584,562	995,522
Current lease payables	426,927	390,589
Other current liabilities	18,216,615	16,754,939
Total current liabilities	70,994,275	67,245,636

Total Shareholders' equity and Liabilities	275,604,667	280,024,095

Consolidated Cash Flow Statement

	3 months 31 March 2026	3 months 31 March 2025
PROFIT FROM OPERATING ACTIVITIES AFTER TAX	830,412	4,036,957
Adjustments to reconcile profit after tax with net cash flows:
Depreciation and impairment of property, plant and machinery	4,447,051	3,511,188
Amortisation and impairment of intangible fixed assets	201,598	189,244
Amortisation of rights of use	140,444	114,988
Financial income	(13,198)	(22,716)
Financial charges	700,871	690,115
Financial charges on financial liabilities for leases	11,048	11,243
Income taxes	619,786	344,345
Gains on the disposal of property, plant and machinery	(16,305)	(44,084)
Current assets write-downs	238,797	142,752
Net change in severance indemnity and pension funds	13,180	52,603
Net change in provisions for risks and charges	174,175	65,000
Net change in deferred tax assets and liabilities	19,598	1,057,675
Interest paid	(698,721)	(678,642)
Changes in working capital:
(Increase)/decrease in inventories	(2,764,592)	(6,858,983)
(Increase)/decrease in trade receivables	(3,080,234)	(5,913,957)
(Increase)/decrease in other non-financial assets and liabilities	(165,221)	280,722
Increase/(decrease) in trade payables	82,477	5,801,002
NET CASH FLOWS FROM OPERATING ACTIVITIES	741,165	2,779,452
Investments:
Investments in tangible fixed assets	(6,740,185)	(10,990,739)
Disposal of tangible fixed assets	17,041	88,713
Investments in intangible fixed assets	(195,553)	(238,898)
NET CASH FLOWS FROM INVESTMENTS	(6,918,697)	(11,140,924)
Financing:
New financing	99,505	2,351,238
Funding repayment	(1,018,679)	(5,225,164)
Principal payments - lease liabilities	(112,747)	(84,271)
Sale/(purchase) of treasury shares	(6,733,935)	-
CASH FLOWS FROM FINANCING	(7,765,856)	(2,958,196)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(13,943,388)	(11,319,668)
Cash and short-term deposits as of 1 January	38,882,901	19,210,213
Cash and short-term deposits as of 31 March	24,939,514	7,890,545

Fine Foods Group - Interim Financial Report as of 30 September 2025

Consolidated Shareholders' Equity Changes Statement

	Share Capital	Legal reserve	Negative reserve for treasury shares in the portfolio	Merger surplus reserve	Share premium reserve	Extraordinary reserve	Other reserves	FTA reserve	Employee benefit reserve	Profits/losses carried forward	Profit/loss for the financial year	Total Shareholders' equity

Balance as of 1 January 2026	22,770,445	5,000,000	(18,722,230)	15,938,641	86,743,750	13,570,047	4,416,281	(6,669,789)	251,002	810,290	10,097,286	134,205,722
Profit/(loss) for the financial year											830,412	830,412
Other income statement components												-
Comprehensive profit/(loss)	-	-	-	-	-	-	-	-	-	-	830,412	830,412
Purchase of treasury shares			(6,733,935)									(6,733,935)
2025 profit allocation										10,097,286	(10,097,286)	-
Balance as of 31 March 2026	22,770,445	5,000,000	(25,456,165)	15,938,641	86,743,750	13,570,047	4,416,281	(6,669,789)	251,002	10,907,576	830,412	128,302,200

Explanatory Notes

Accounting Standards and consolidation area

The Fine Foods Group's Interim Financial Report as of 31 March 2026 has been prepared under the Stock Exchange Regulations, which set the publication of quarterly financial information as a requirement for maintaining a listing on the Euronext STAR Milan segment.

The Interim Financial Report has been prepared under the International Accounting Standards (IAS) and International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) and the interpretations of the IFRS Interpretations Committee (IFRSIC) and the Standing Interpretations Committee (SIC), recognised in the European Union under (EC) Regulation no. 1606/2002 applicable at the end of the period. The accounting standards and assessment criteria adopted to prepare this Interim Financial Report are consistent with those used in the 31 December 2025 Financial Statements to which reference is made.

The scope of consolidation as of 31 March 2026 includes the Parent Company Fine Foods & Pharmaceuticals N.T.M. S.p.A., and the subsidiary Fine Cosmetics S.p.A.

The Interim Financial Report as of 31 March 2026 is not subject to auditing by the auditing company.

Net Financial Position

The diagram below shows the net financial debt under Consob recommendation of 21 April 2021 and ESMA32-382-1138 guidelines.

Thousands of Euro	31 March 2026	31 December 2025
A. Liquid assets	24,940	38,883
B. Cash or cash equivalents	-	-
C. Other current financial assets	-	-
D. Liquidity (A) + (B) + (C)	24,940	38,883
E. Current financial receivables	-	-
E. Current financial debt (including debt instruments, but excluding the current portion of non-current financial debt)	528	1,392
F. Current portion of non-current financial debt	14,230	11,751
G. Current financial debt (E + F)	14,759	13,143
- guaranteed	-	-
- secured by collateral	273	272
- not guaranteed	14,485	12,871
H. Net current financial debt (G - D)	(10,181)	(25,740)
I. Non-current financial debt (excluding current portion and debt instruments)	71,185	73,636
J. Debt instruments	-	-
K. Trade payables and other non-current payables	-	-
L. Non-current financial debt (I + J + K)	71,185	73,636
- guaranteed	-	-
- secured by collateral	2,664	2,732
- not guaranteed	68,521	70,815
M. Total Financial Debt (H + L)	61,004	47,896

Reclassified Balance Sheet

For a better understanding of the Company's balance sheet and financial position, a reclassified Balance Sheet is provided below.

Working capital	31 March 2026	31 December 2025
Inventories	37,531,333	34,954,626
Trade receivables	39,635,988	36,606,666
Other current assets	8,695,940	6,906,755
Trade payables	(36,434,448)	(36,351,971)
Other current liabilities	(19,801,177)	(17,750,461)
Total working capital (A)	29,627,636	24,365,615
Fixed assets	31 March 2026	31 December 2025
Tangible fixed assets	146,450,186	144,157,789
Intangible assets and rights of use	16,376,502	16,326,903
Other receivables and non-current assets	1,975,203	2,188,455
Employee severance indemnities and other provisions	(5,123,688)	(4,936,954)
Total fixed assets (B)	159,678,203	157,736,193
Net Invested Capital (A) + (B)	189,305,839	182,101,808
Sources	31 March 2026	31 December 2025
Shareholders' equity	128,302,199	134,205,722
Net financial debt	61,003,640	47,896,096
Total Sources	189,305,839	182,101,808

Net invested capital as of 31 March 2026 was €189.3 million (€182.1 million as of 31 December 2025) and was covered by:

Shareholders' equity of €128.3 million (€134.2 million as of 31 December 2025); Fine Foods repurchased €6.7 million of
treasury shares in Q1 2026.
The Group's Net Financial Position as of 31 March 2026 of €61.0 million, with a negative change of €13.1 million compared to €47.9 million as of 31 December 2025. Operations generated a positive cash flow of €2.0 million before capital expenditure. This was mainly offset by net investments (€7.1 million) made in the period and the purchase of treasury shares (€6.7 million).

Working capital as of 31 March 2026 was €29.6 million (€24.4 million at the end of the previous financial year). Specifically, Trade Net Working Capital of €40.7 million increased by €5.5 million compared to 31 December 2025, mainly due to higher inventories (€2.6 million) and trade receivables (€3.0 million).

Tangible Fixed Assets increased by €2.3 million in Q1 2026, due to net investments of €6.7 million and depreciation for the period of

€4.4 million. Significant additional extraordinary investments amounting to €4.6 million were made during the reporting period, with most of these funds used to purchase new machinery and equipment for installation at the new pharmaceutical facility in Brembate. Intangible fixed assets and rights of use were €16.4 million as of 31 March 2026 (compared to €16.3 million at the end of FY 2025).

Reclassified Income Statement

To better understand the Company's operating results, a reclassification of the Income Statement is provided below.

Item	31 March 2026	%	31 March 2025	%	Absolute change	% Changes
Revenue from contracts with customers	58,448,942	100.0%	62,996,851	100.0%	(4,547,909)	(7.2%)
Costs for consumption of raw materials,
change in inventories of finished goods	(30,505,221)	(52.2%)	(33,714,597)	(53.5%)	3,209,376	(9.5%)
and work in progress.
INDUSTRIAL ADDED VALUE	27,943,721	47.8%	29,282,255	46.5%	(1,338,533)	(4.6%)
Other revenue and income	276,509	0.5%	301,280	0.5%	(24,771)	(8.2%)
Costs for services	(6,712,362)	(11.5%)	(5,909,711)	(9.4%)	(802,651)	13.6%
Personnel costs	(14,177,645)	(24.3%)	(13,295,829)	(21.1%)	(881,816)	6.6%
Other operating costs	(372,613)	(0.6%)	(487,586)	(0.8%)	114,972	(23.6%)
EBITDA	6,957,611	11.9%	9,890,410	15.7%	(2,932,799)	(29.7%)
ADJUSTED EBITDA	7,223,855	12.4%	10,197,010	16.2%	(2,973,155)	(29.2%)
Amortisation, depreciation, and impairment losses	(4,789,093)	(8.2%)	(3,815,421)	(6.1%)	(973,672)	25.5%
EBIT	2,168,517	3.7%	6,074,989	9.6%	(3,906,471)	(64.3%)
ADJUSTED EBIT	2,434,762	4.2%	6,381,589	10.1%	(3,946,827)	(61.8%)
Financial income	13,198	0.0%	22,716	0.0%	(9,518)	(41.9%)
Financial charges	(711,919)	(1.2%)	(701,358)	(1.1%)	(10,560)	1.5%
INCOME BEFORE TAXES	1,469,796	2.5%	5,396,347	8.6%	(3,926,550)	(72.8%)
ADJUSTED INCOME BEFORE TAXES	1,736,041	3.0%	5,702,947	9.1%	(3,966,906)	(69.6%)
Income taxes	(639,384)	(1.1%)	(1,359,389)	(2.2%)	720,005	(53.0%)
Profit (loss) for the financial year	830,412	1.4%	4,036,957	6.4%	(3,206,545)	(79.4%)
ADJUSTED income/(loss)	1,022,375	1.7%	4,258,016	6.8%	(3,235,642)	(76.0%)

The table below shows the reconciliation of Industrial Added Value, EBITDA, EBIT, Income before taxes, and Profit (Loss) for the period, and the Adjusted related values.

Industrial Added Value was determined using the following income statement classification:
	31 March 2026	31 March 2025
Revenue from contracts with customers	58,448,942	62,996,851
Costs for consumption of raw materials, change in inventories of finished goods and work in progress	(30,505,221)	(33,714,597)
Industrial Added Value	27,943,721	29,282,255
The diagram below shows the definition of the subtotals for the other income statement items.
	31 March 2026	31 March 2025
Profit/(loss) for the financial year (1)	830,412	4,036,957
Income taxes	(639,384)	(1,359,389)
Income before taxes (2)	1,469,796	5,396,347

Financial charges	711,919	701,358
Financial income	(13,198)	(22,716)
EBIT (3)	2,168,517	6,074,989
Amortisation	4,789,093	3,815,421
EBITDA (4)	6,957,611	9,890,410

Extraordinary and non-recurring items impacting EBITDA, that have been adjusted during 2025 and 2026, are shown in the table below. For further details, refer to what is reported below.

Non-recurring income and charges attributable to Fine Foods Non-recurring income and charges attributable to Fine Cosmetics

31 March 2026

266,245

31 March 2025

256,747

49,853

Total non-recurring income and charges (5)

266,245

306,601

As a result of these non-recurring costs, Adjusted EBITDA, Adjusted EBIT and Adjusted income before taxes and Adjusted profit (loss) are shown in the table below.

ADJ EBITDA (4) + (5)	7,223,855	10,197,010
ADJ EBIT (3) + (5)	2,434,762	6,381,589
Income before taxes (2)	1,469,796	5,396,347
Non-recurring income and charges (5)	266,245	306,601
ADJ income before taxes (2) + (5)	1,736,041	5,702,947
Income taxes	(639,384)	(1,359,389)
tax effect on non-recurring income and charges (5)	(74,282)	(85,542)
ADJ income/(loss)	1,022,375	4,258,016

Revenue from sales and services went from €63.0 million as of 31 March 2025 to €58.4 million as of 31 March 2026, with a decrease of 7.2%. Below are the details for each Business Unit:

(Amounts in Euro units)	31 March 2026	31 March 2025
Business Unit - Nutra	30,170,492	36,765,856
Business Unit - Pharma	21,542,722	20,062,846
Business Unit - Cosmetics	6,735,728	6,168,149
Total Revenue from contracts with customers	58,448,942	62,996,851

The Nutra Business Unit, which represents 51.6% of the Group's business, generated revenue of €30.2 million in Q1 2026, with a decrease of 17.9% compared with the same period of the previous year.

The Pharma Business Unit, accounting for 36.9% of the Group's business, continued its growth trajectory, achieving a 7.4% increase in turnover compared to the same period in 2025, reaching €21.5 million in revenue as of 31 March 2026.

Cosmetics Business Unit revenue, accounting for 11.5% of the Group's business, reached €6.7 million in Q1 2026, up 9.2% compared to the figure recorded as of 31 March 2025.

Raw material costs on sales revenue ratio, of approximately 52.2%, decreased compared to what was shown in the Interim Financial Report as of 31 March 2025 (53.5%).

Service costs increased from €5.9 million in Q1 2025 to €6.7 million in Q1 2026, representing a 13.6% growth. This change resulted from higher maintenance costs for certain plant facilities (+€143,000), increased expenses for attending trade fairs and events (+€114,000), greater spending on external analyses (+€110,000), and consultancy fees for strategic development projects (+€103,000) compared to 31 March 2025.

Personnel costs were €14.2 million, with an increase of €0.9 million compared to the same period of 2025.

As of 31 March 2026, EBITDA was €7.0 million (a 11.9% EBITDA margin), compared to €9.9 million (a 15.7% EBITDA Margin) in Q1

2025.

The Group's adjusted EBITDA was €7.2 million (12.4% adjusted EBITDA margin) for the first quarter, compared to €10.2 million (16.2% adjusted EBITDA margin) as of 31 March 2025.

The decrease stemmed from reduced fixed cost absorption, which was a result of lower volumes in the Nutra business unit. The period's performance reflected additional costs of starting the new pharmaceutical plant in Brembate, with revenue projected to rise throughout the year and improve the plant utilisation rate.

The following non-recurring expenses were incurred in Q1 2026, impacting EBITDA:

An additional €176,000 was allocated to the risk provision for salary differences;
M&A advisory costs were €90,000.
The following non-recurring expenses were incurred in 2025, impacting EBITDA:
Operating expenses of €172,000, including personnel costs for employees and temporary staff, were incurred to support the
start-up of the new pharmaceutical facility;
Severance and redundancy incentives were €85,000;
An additional €50,000 was allocated to the risk provision for salary differences.

Adjusted EBIT was €2.4 million as of 31 March 2026 (Adjusted EBIT of €6.4 million as of 31 March 2025). As of 31 March 2026, EBIT

was impacted by €902,000 in depreciation and amortisation expenses related to the expansion of the pharmaceutical plant. The Adjusted net result in Q1 2026 was €1.0 million (compared to €4.3 million in Q1 2025).

Events following the end of the period

On April 17, 2026, Fine Foods announced that it had signed a binding agreement with Alfasigma S.p.A., a pharmaceutical company headquartered in Italy with more than 75 years of experience, to acquire all of the share capital of Sofar S.p.A., an Alfasigma subsidiary with a manufacturing facility in Trezzano Rosa (Milano).

The transaction aligns with Fine Foods' industrial strategy to strengthen and broaden its production capabilities. The acquisition allows Fine Foods to add expertise and technology for producing liquid and semi-solid pharmaceutical forms, expanding its industrial capabilities. By completing this transaction, the company broadens its service portfolio, reinforces Fine Foods' competitive role as a strategic and integrated partner, and enhances its capability to secure new projects and customers. The acquisition of all Sofar shares confirms operational and organisational continuity, while enhancing the industrial partnership with Alfasigma, which will retain ownership of products currently manufactured at Trezzano Rosa. Alfasigma and Fine Foods will keep manufacturing and supplying their products under a long-term contract.

On 22 April 2026, Fine Foods informed the Presidency of the Council of Ministers of the acquisition as required by Decree Law 21 of 15 March 2012, as converted with amendments by Law No. 56 of 11 May 2012, as amended, ("Golden Power" regulation). Under applicable regulations, the Golden Power procedure must be completed within 45 days of notification, unless suspended or extended. Fine Foods will notify the market of the results as required by applicable regulations, including the relevant regulatory framework.

The completion is expected in the first half of June.

Business outlook

As highlighted at the end of 2025, the market segments in which the Group operates are expected to grow in Europe and globally in the coming years. The nutraceutical segment focused on weight-control products is undergoing a transformation, driven by emerging trends in the customisation of food supplements to meet individual needs.

Meanwhile, the main players in the Health & Beauty sector are increasingly outsourcing, opting for integrated partners to develop and manufacture nutraceutical, pharmaceutical, and cosmetics solutions. This shift supports asset-light business models that emphasise advanced research and brand management.

Fine Foods & Pharmaceuticals N.T.M. S.p.A. aims to strengthen its competitive position by expanding its market share across its three core business units-Nutra, Pharma, and Cosmetics-enhancing their synergies.

The Group announced on 17 April 2026 the upcoming acquisition of all shares in Sofar S.p.A. from Alfasigma S.p.A., and Sofar's results will be consolidated starting in June, effective as of 1 January 2026. The Group is actively exploring further growth opportunities through external expansion to enhance the variety of its products, including different pharmaceutical forms and packaging options.

Despite challenges, the Nutra BU is advancing its development, prioritising quality, innovation, and value-added services. This financial year is expected to show a mixed evolution: while innovation-driven segments are growing, some categories - particularly weight management - are experiencing volume pressure, influenced by lower consumption, also in relation to GLP-1 therapies, and supply chain destocking. Quantifying the full scope of these effects presents challenges due to broader macroeconomic conditions. Nutra BU is likely to gain from new partnerships. The Group confirms its plan to boost the Nutra BU's production capacity and develop new forms and technologies. This strategy is intended to enhance its competitiveness and support growth over the medium to long term.

The Pharma BU, which grew rapidly also in Q1 2026, will focus on managing higher volumes through multi-year agreements with top international customers. The Group will keep improving output at current sites and integrate Sofar S.p.A.'s Trezzano Rosa site. Production at the expanded Brembate facility is underway, and its output is expected to steadily contribute to revenue growth throughout 2026.

Following a phase of integration, reorganisation, and optimisation, supported by targeted investments, a new cosmetics development laboratory and strengthened management, the Cosmetics BU continues to deliver positive results. Fine Cosmetics is projected towards a future of innovation and strategic partnerships in the international Beauty and Personal Care industry. Its contribution to the Group's development is expected to strengthen in 2026.

Due to the nature of the business, Fine Foods Group's revenue may fluctuate from one quarter to the next and may not always provide a meaningful basis for comparison. The order book, ongoing multi-year contracts, and the development pipeline provide visibility into business evolution and offer support for consistent profitability growth over the medium to long term.

The Group will continue its commitment to sustainability, strengthening its role as a reference partner for its customers, and provide solutions that are increasingly aligned with the growing ESG market expectations.

Verdellino-Zingonia,

For the Board of Directors Chairman

Marco Francesco Eigenmann

Declaration of the Manager in charge under Article 154-bis of Legislative Decree no. 58/98

Under paragraph 2 of Article 154-bis of Legislative Decree no. 58/1998 (Consolidated Law on Finance - TUF), the Manager in charge of preparing the company's financial reports, Pietro Bassani, certifies that the accounting information contained in the Interim Financial Report as of 31 March 2026 of Fine Foods & Pharmaceuticals N.T.M. S.p.A. reflects the accounting documents, books and records.

Verdellino-Zingonia, 07 May 2026

Managing Director

Pietro Oriani

The Manager preparing the corporate accounts

Pietro Bassani

This Interim Financial Report has been translated into English solely for the convenience of the international reader. In the event of conflict or inconsistency between the terms used in the Italian version of the report and the English version, the Italian version shall prevail, as the Italian version constitutes the sole official document.